Butyrophilin subfamily 3 member A1 (BTN3A1)–phosphoantigen complex (BTN3A1–pAg complex)

Butyrophilin subfamily 3 member A1 (BTN3A1), also known as CD277, is a transmembrane protein essential for the activation of Vγ9Vδ2 T cells, a subset of gamma-delta T cells involved in innate-like immunosurveillance (Harly et al., 2012, Nature Immunology). The target specifically refers to the complex formed when intracellular phosphoantigens (pAg), such as isopentenyl pyrophosphate (IPP), bind to the intracellular B30.2 domain of BTN3A1 (Vavassori et al., 2013, Nature Immunology). This binding event triggers a "molecular switch" that induces a conformational change in the extracellular domain of BTN3A1, which is then recognized by the Vγ9Vδ2 T-cell receptor (TCR) (Salim et al., 2017, ACS Chemical Biology). In many tumor cells, dysregulated mevalonate metabolism leads to the accumulation of pAg, making the BTN3A1–pAg complex a critical signal for T-cell-mediated killing. Therapeutic strategies, such as the monoclonal antibody ICT01, aim to stabilize this active conformation or mimic pAg binding to enhance the anti-tumor immune response (ImCheck Therapeutics, 2024). This approach is currently being evaluated in clinical trials for various solid and hematological malignancies to leverage the potent, non-MHC-restricted cytotoxic activity of gamma-delta T cells.

Other names

CD277–phosphoantigen complexBTN3A1–pAg complexButyrophilin 3A1–phosphoantigen complexBTN3A1–isopentenyl pyrophosphate complex

Agonistic monoclonal antibodies or accumulated intracellular phosphoantigens induce a conformational change in the BTN3A1 protein, specifically involving the B30.2 domain and the juxtamembrane region, which is then recognized by the Vγ9Vδ2 T-cell receptor to trigger anti-tumor cytotoxicity.